Document:

Third Supplemental Indenture - Generics Bidco II, LLC

 Exhibit 4.18 
 THIRD SUPPLEMENTAL INDENTURE 
 THIRD SUPPLEMENTAL
INDENTURE (this “Third Supplemental Indenture”), dated as of September 26, 2011, among Generics Bidco II, LLC, a Delaware limited liability company, Generics International (US Holdco), Inc., a Delaware
corporation, Generics International (US Midco), Inc., a Delaware corporation, Generics International (US Parent), Inc., a Delaware corporation, Moores Mill Properties L.L.C., a Delaware limited liability company, Quartz Specialty Pharmaceuticals,
LLC, a Delaware limited liability company, and Wood Park Properties LLC, a Delaware limited liability company (collectively, the “Guaranteeing Subsidiaries”), each a subsidiary of Endo Pharmaceuticals Holdings Inc. (or its permitted
successor), a Delaware corporation (the “Company”), the Company, the other Guarantors (as defined in the Indenture referred to herein) and Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the
“Trustee”). 
 W I T N E S S E T H 

WHEREAS, the Company has heretofore executed and delivered to the Trustee an indenture (the
“Indenture”), dated as of June 8, 2011, providing for the issuance of 7  1/4% Senior Notes due 2022 (the “Notes”); 
 WHEREAS, the
Indenture provides that under certain circumstances the Guaranteeing Subsidiaries shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiaries shall unconditionally guarantee all of the
Company’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the “Note Guarantee”); and 
 WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee is authorized to execute and deliver this Third Supplemental Indenture. 

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby
acknowledged, the Guaranteeing Subsidiaries and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 
 1. CAPITALIZED TERMS. Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture. 

2. AGREEMENT TO GUARANTEE. Each of the Guaranteeing Subsidiaries hereby agrees to provide an
unconditional Guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including but not limited to Article 10 thereof. 
 4. NO RECOURSE AGAINST OTHERS. No director, officer, employee, incorporator or stockholder of the Company or any Guarantor, as such, will have
any liability for any obligations of the Company or the Guarantors under the Notes, this Indenture, the Note Guarantees or for any claim based on, in respect of, or by reason of, 

  
 1 

 
such obligations or their creation. Each Holder of Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the
Notes. The waiver may not be effective to waive liabilities under the federal securities laws. 
 5. NEW
YORK LAW TO GOVERN; WAIVER OF JURY TRIAL. THIS THIRD SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF NEW YORK. THE COMPANY, THE TRUSTEE AND EACH OF THE GUARANTORS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR
RELATING TO THIS THIRD SUPPLEMENTAL INDENTURE OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 6. COUNTERPARTS. The
parties may sign any number of copies of this Third Supplemental Indenture. Each signed copy (which may be provided via facsimile or other electronic transmission) shall be an original, but all of them together represent the same agreement.

 7. EFFECT OF HEADINGS. The Section headings herein are for convenience only and
shall not affect the construction hereof. 
 8. THE TRUSTEE. The Trustee shall not be responsible
in any manner whatsoever for or in respect of the validity or sufficiency of this Third Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiaries, the other
Guarantors and the Company. 

 IN WITNESS WHEREOF, the parties hereto have caused this Third Supplemental Indenture to be
duly executed and attested, all as of the date first above written. 
  

					
	GUARANTEEING SUBSIDIARIES:
	
	GENERICS BIDCO II, LLC
		 	 By: GENERICS INTERNATIONAL
 (US), INC., its sole manager

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	GENERICS INTERNATIONAL (US HOLDCO), INC.
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	GENERICS INTERNATIONAL (US MIDCO), INC.
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	GENERICS INTERNATIONAL (US PARENT), INC.
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

 
					
	MOORES MILL PROPERTIES L.L.C.
		 	 By: GENERICS INTERNATIONAL
 (US), INC., its sole manager

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	 QUARTZ SPECIALTY

PHARMACEUTICALS, LLC

		 	 By: GENERICS INTERNATIONAL
 (US), INC., its sole manager

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	WOOD PARK PROPERTIES LLC
		 	 By: GENERICS INTERNATIONAL
 (US), INC., its sole manager

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

 
					
	COMPANY:
	
	 ENDO PHARMACEUTICALS

HOLDINGS INC.

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	GUARANTORS:
	
	ENDO PHARMACEUTICALS INC.
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	 ENDO PHARMACEUTICALS

SOLUTIONS INC.

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	 ENDO PHARMACEUTICALS VALERA
 INC.

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	GENERICS INTERNATIONAL (US), INC.
		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

 
					
	GENERICS BIDCO I, LLC
		 	 By GENERICS INTERNATIONAL
 (US), INC., its sole manager

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	VINTAGE PHARMACEUTICALS, LLC
		 	 By GENERICS INTERNATIONAL
 (US), INC., its sole manager

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	LEDGEMONT ROYALTY SUB LLC
		 	 By ENDO PHARMACEUTICALS
 SOLUTIONS INC., its sole manager

		
	By:	 	 /s/ Alan G. Levin

		 	Name:	 	Alan G. Levin
		 	Title:	 	 Executive Vice President and

Chief Financial Officer

	
	 AMERICAN MEDICAL SYSTEMS
 HOLDINGS, INC.

		
	By:	 	 /s/ Caroline B. Manogue

		 	Name:	 	Caroline B. Manogue
		 	Title:	 	 Executive Vice President,

Chief Legal Officer and Secretary

 
					
	AMERICAN MEDICAL SYSTEMS, INC.
		
	 By:
	 	 /s/ Caroline B. Manogue

		 	Name:	 	Caroline B. Manogue
		 	Title:	 	 Executive Vice President,

Chief Legal Officer and Secretary

	
	 AMS RESEARCH CORPORATION

		
	 By:
	 	 /s/ Caroline B. Manogue

		 	Name:	 	Caroline B. Manogue
		 	Title:	 	 Executive Vice President,

Chief Legal Officer and Secretary

	
	 AMS SALES CORPORATION

		
	 By:
	 	 /s/ Caroline B. Manogue

		 	Name:	 	Caroline B. Manogue
		 	Title:	 	 Executive Vice President,

Chief Legal Officer and Secretary

	
	 LASERSCOPE

		
	 By:
	 	 /s/ Caroline B. Manogue

		 	Name:	 	Caroline B. Manogue
		 	Title:	 	 Executive Vice President,

Chief Legal Officer and Secretary

 
			
	TRUSTEE:
	
	 WELLS FARGO BANK, NATIONAL ASSOCIATION,
 as Trustee

		
	By:	 	 /s/ Martin G. Reed

		 	Name: Martin G. Reed
		 	Title:   Vice PresidentSTATE OF DELAWARE 

CERTIFICATE OF AMENDMENT

OF CERTIFICATE OF INCORPORATION

 

The corporation organized and existing under
and by virtue of the General Corporation Law of the State of Delaware does hereby certify:

 

FIRST: That
at a meeting of the Board of Directors of Amarantus BioSciences, Inc. resolutions were duly adopted setting forth a proposed
amendment of the Certificate of Incorporation of said corporation, declaring said amendment to be advisable and calling a meeting
of the stockholders of said corporation for consideration thereof. The resolution setting forth the proposed amendment is as follows:

 

RESOLVED that Article IV, Section A of the Corporation’s Certificate
of Incorporation be amended to change total number of authorized shares of Common Stock of the Corporation to 250,000,000 shares.
As amended, Articled IV, Section A shall read as follows:

 

A.CLASSES OF STOCK

 

The Corporation is authorized to issue
two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number
of shares which the Corporation is authorized to issue is 260,000,000 shares. 250,000,000 shares shall be Common Stock, each having
a par value of $0.001. 10,000,000 shares shall be Preferred Stock, each having a par value of $0.001.

 

SECOND: That thereafter, pursuant to
resolution of its Board of Directors, a special meeting of the stockholders of said corporation was duly called and held upon notice
in accordance with Section 222 of the General Corporation Law of the State of Delaware at which meeting the necessary number of
shares as required by statute were voted in favor of the amendment.

 

THIRD: That said amendment was duly
adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

 

IN WITNESS WHEREOF, said corporation
has caused this certificate to be signed this 7th day of October, 2011.

 

 

/s/ Martin D. Cleary

Martin D. Cleary

President and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]